SHWZ Quote, Financials, Valuation and Earnings

HealthWarehouse.com has a net margin of -32.23% compared to Medicine Man Technologies's net margin of 0.82%. Medicine Man Technologies's return on equity of -39.36% beat HealthWarehouse.com's return on equity of --.

Medicine Man Technologies has a consensus price target of $2.64, signalling upside risk potential of 26303.3%. On the other hand HealthWarehouse.com has an analysts' consensus of -- which suggests that it could grow by 687.88%. Given that Medicine Man Technologies has higher upside potential than HealthWarehouse.com, analysts believe Medicine Man Technologies is more attractive than HealthWarehouse.com.

Medicine Man Technologies has a beta of 2.010, which suggesting that the stock is 101.023% more volatile than S&P 500. In comparison HealthWarehouse.com has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.26%.

Medicine Man Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HealthWarehouse.com offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicine Man Technologies pays -- of its earnings as a dividend. HealthWarehouse.com pays out -- of its earnings as a dividend.

Medicine Man Technologies quarterly revenues are $43.2M, which are larger than HealthWarehouse.com quarterly revenues of $9M. Medicine Man Technologies's net income of -$13.9M is lower than HealthWarehouse.com's net income of $73.8K. Notably, Medicine Man Technologies's price-to-earnings ratio is -- while HealthWarehouse.com's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicine Man Technologies is 0.00x versus 0.18x for HealthWarehouse.com. Usually stocks with elevated PS ratios are considered overvalued.

Ladybug Resource Group has a net margin of -32.23% compared to Medicine Man Technologies's net margin of --. Medicine Man Technologies's return on equity of -39.36% beat Ladybug Resource Group's return on equity of --.

Medicine Man Technologies has a consensus price target of $2.64, signalling upside risk potential of 26303.3%. On the other hand Ladybug Resource Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicine Man Technologies has higher upside potential than Ladybug Resource Group, analysts believe Medicine Man Technologies is more attractive than Ladybug Resource Group.

Medicine Man Technologies has a beta of 2.010, which suggesting that the stock is 101.023% more volatile than S&P 500. In comparison Ladybug Resource Group has a beta of -9.113, suggesting its less volatile than the S&P 500 by 1011.333%.

Medicine Man Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ladybug Resource Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicine Man Technologies pays -- of its earnings as a dividend. Ladybug Resource Group pays out -- of its earnings as a dividend.

Medicine Man Technologies quarterly revenues are $43.2M, which are larger than Ladybug Resource Group quarterly revenues of --. Medicine Man Technologies's net income of -$13.9M is higher than Ladybug Resource Group's net income of --. Notably, Medicine Man Technologies's price-to-earnings ratio is -- while Ladybug Resource Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicine Man Technologies is 0.00x versus -- for Ladybug Resource Group. Usually stocks with elevated PS ratios are considered overvalued.

SunLink Health Systems has a net margin of -32.23% compared to Medicine Man Technologies's net margin of -6.93%. Medicine Man Technologies's return on equity of -39.36% beat SunLink Health Systems's return on equity of -5.08%.

Medicine Man Technologies has a consensus price target of $2.64, signalling upside risk potential of 26303.3%. On the other hand SunLink Health Systems has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicine Man Technologies has higher upside potential than SunLink Health Systems, analysts believe Medicine Man Technologies is more attractive than SunLink Health Systems.

Medicine Man Technologies has a beta of 2.010, which suggesting that the stock is 101.023% more volatile than S&P 500. In comparison SunLink Health Systems has a beta of 1.398, suggesting its more volatile than the S&P 500 by 39.847%.

Medicine Man Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SunLink Health Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicine Man Technologies pays -- of its earnings as a dividend. SunLink Health Systems pays out -- of its earnings as a dividend.

Medicine Man Technologies quarterly revenues are $43.2M, which are larger than SunLink Health Systems quarterly revenues of $7.9M. Medicine Man Technologies's net income of -$13.9M is lower than SunLink Health Systems's net income of -$549K. Notably, Medicine Man Technologies's price-to-earnings ratio is -- while SunLink Health Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicine Man Technologies is 0.00x versus 0.23x for SunLink Health Systems. Usually stocks with elevated PS ratios are considered overvalued.

Walgreens Boots Alliance has a net margin of -32.23% compared to Medicine Man Technologies's net margin of -8%. Medicine Man Technologies's return on equity of -39.36% beat Walgreens Boots Alliance's return on equity of -43.52%.

Medicine Man Technologies has a consensus price target of $2.64, signalling upside risk potential of 26303.3%. On the other hand Walgreens Boots Alliance has an analysts' consensus of $10.43 which suggests that it could grow by 7.85%. Given that Medicine Man Technologies has higher upside potential than Walgreens Boots Alliance, analysts believe Medicine Man Technologies is more attractive than Walgreens Boots Alliance.

Medicine Man Technologies has a beta of 2.010, which suggesting that the stock is 101.023% more volatile than S&P 500. In comparison Walgreens Boots Alliance has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.445%.

Medicine Man Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Walgreens Boots Alliance offers a yield of 10.34% to investors and pays a quarterly dividend of $0.25 per share. Medicine Man Technologies pays -- of its earnings as a dividend. Walgreens Boots Alliance pays out -14.59% of its earnings as a dividend.

Medicine Man Technologies quarterly revenues are $43.2M, which are smaller than Walgreens Boots Alliance quarterly revenues of $37.5B. Medicine Man Technologies's net income of -$13.9M is higher than Walgreens Boots Alliance's net income of -$3B. Notably, Medicine Man Technologies's price-to-earnings ratio is -- while Walgreens Boots Alliance's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicine Man Technologies is 0.00x versus 0.06x for Walgreens Boots Alliance. Usually stocks with elevated PS ratios are considered overvalued.